A
András Harsányi
Researcher at Eötvös Loránd University
Publications - 27
Citations - 331
András Harsányi is an academic researcher from Eötvös Loránd University. The author has contributed to research in topics: Reimbursement & Biosimilar. The author has an hindex of 9, co-authored 26 publications receiving 250 citations.
Papers
More filters
Journal ArticleDOI
Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: A neuropsychological study
TL;DR: Both treatment methods seem effective in reducing OCD symptoms and cognitive deficits, but, importantly, to different degrees.
Journal ArticleDOI
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Paweł Kawalec,Ewa Stawowczyk,Tomas Tesar,Jana Skoupa,Adina Turcu-Stiolica,Maria Dimitrova,Guenka Petrova,Zinta Rugaja,Agnes Männik,András Harsányi,Pero Draganić +10 more
TL;DR: The requirements for the pricing and reimbursement of biosimilar products as well as the access of patients to biologic treatment do not differ significantly between the considered CEE countries.
Journal ArticleDOI
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
Paweł Kawalec,Tomas Tesar,Lenka Vostalova,Pero Draganić,Manoela Manova,Alexandra Savova,Guenka Petrova,Zinta Rugaja,Agnes Männik,Christoph Sowada,Ewa Stawowczyk,András Harsányi,András Inotai,Adina Turcu-Stiolica,Jolanta Gulbinovič,Andrzej Pilc,Andrzej Pilc +16 more
TL;DR: Review of reimbursement environment as well as pricing and reimbursement requirements for drugs in selected Central and Eastern Europe (CEE) countries revealed that pricing criteria for drugs, employed in the CEE countries, were quite similar.
Journal ArticleDOI
Two types of impairments in OCD: Obsessions, as problems of thought suppression; compulsions, as behavioral-executive impairment
TL;DR: It is concluded that obsessions indicate a failure of cognitive inhibition but do not involve significant impairment of executive functions, whereas compulsions indicate ineffective behavior inhibition and impaired executive functions.
Journal ArticleDOI
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Brian Godman,Brian Godman,Brian Godman,Mainul Haque,Trudy Leong,Eleonora Allocati,Santosh Kumar,Salequl Islam,Jaykaran Charan,Farhana Akter,Amanj Kurdi,Amanj Kurdi,Amanj Kurdi,Carlos Vassalo,Muhammed Abu Bakar,Sagir Abdur Rahim,Nusrat Sultana,Farzana Deeba,M. A. Halim Khan,A. B.M.Muksudul Alam,Iffat Jahan,Zubair Mahmood Kamal,Humaira Hasin,Munzur-E-Murshid,Shamsun Nahar,M. E. Haque,Siddhartha Dutta,Jha Pallavi Abhayanand,Rimple Jeet Kaur,Godfrey Mutashambara Rwegerera,Renata Cristina Rezende Macedo do Nascimento,Isabella Piassi Godói,Mohammed Irfan,Adefolarin A. Amu,Patrick Matowa,Joseph Acolatse,Robert Incoom,Israel Abebrese Sefah,Jitendra Acharya,Sylvia Opanga,Lisper Wangeci Njeri,David Kimonge,Hye Young Kwon,Seung Jin Bae,Karen Koh Pek Khuan,Abdullahi Rabiu Abubakar,Ibrahim Haruna Sani,Tanveer Ahmed Khan,Shahzad Hussain,Zikria Saleem,Oliver Ombeva Malande,Thereza Piloya-Were,Rosana Gambogi,Carla Hernandez Ortiz,Luke Alutuli,Aubrey Chichonyi Kalungia,Iris Hoxha,Vanda Marković-Peković,Biljana Tubić,Guenka Petrova,Konstantin Tachkov,Ott Laius,András Harsányi,András Inotai,Arianit Jakupi,Svens Henkuzens,Kristina Garuoliene,Jolanta Gulbinovič,Magdalene Wladysiuk,Jakub Rutkowski,Ileana Mardare,Jurij Fürst,Stuart McTaggart,Sean MacBride-Stewart,Caridad Pontes,Caridad Pontes,Corinne Zara,Eunice Twumwaa Tagoe,Rita Banzi,Janney Wale,Mihajlo Jakovljevic,Mihajlo Jakovljevic +81 more
TL;DR: In this paper, the authors assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of insulin analogue biosimilars to benefit all key stakeholders.